Microbot Medical Inc. (NASDAQ: MBOT)

Microbot Medical Inc. is a medical device company that researches, designs, and develops next-generation robotic endoluminal surgery devices for the minimally invasive surgery market. The company focuses on its LIBERTY technological platform to create the first fully disposable robotic system for endovascular procedures, enabling remote manipulation of guidewires and catheters within the vasculature. This system aims to eliminate the need for large capital equipment, dedicated catheterization laboratory rooms, and specialized staff while reducing radiation exposure and physical strain on physicians.

Microbot Medical Inc. generates revenue primarily from the sale of its LIBERTY Endovascular Robotic Surgical System and associated disposable components, with additional potential revenue from its NovaCross product line. The company has initiated a limited market release in selected high-volume U. S. regions and reports adoption by hospitals such as Emory University Hospital and Tampa General Hospital. Revenue is derived from selling the robotic platform to hospitals, interventional radiology centers, and catheterization laboratories seeking to improve procedural efficiency and safety.

Within the emerging field of endovascular robotics, Microbot Medical Inc. positions itself as an innovator with a fully disposable, compact system that contrasts with competitors requiring reusable capital equipment and extensive setup. Its main rival is the CorPath GRX system from Corindus Vascular Robotics, a Siemens Healthineers business, while other competitors include the R-One+ device by Robocath and several early-stage developers such as LN Robotics, Nanoflex Robotics, UAB Inovatyvi medicina, and Endoways. Microbot’s competitive advantages include the system’s disposable nature, reduced need for dedicated cath-lab infrastructure, lower upfront costs, compatibility with a wide range of guidewires and microcatheters, and potential for tele‑procedural applications.

Microbot Medical Inc. serves hospitals and interventional radiology providers that perform peripheral vascular, coronary, and neurovascular procedures. Specific customers adopting the LIBERTY system include Emory University Hospital and Tampa General Hospital, with additional collaborations involving Corewell Health for research and training initiatives. The company’s target clientele comprises medical facilities seeking to enhance procedural access, reduce operator radiation exposure, and improve procedural efficiency through robotic assistance.